These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 27041584)
1. CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation. Zhang P; Feng S; Liu G; Wang H; Fu A; Zhu H; Ren Q; Wang B; Xu X; Bai H; Dong C Oncogene; 2016 Sep; 35(38):5056-5069. PubMed ID: 27041584 [TBL] [Abstract][Full Text] [Related]
2. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines. Kim YI; Shin MK; Lee JW; Chung JH; Lee MH Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457 [TBL] [Abstract][Full Text] [Related]
3. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. Miyake H; Eto H; Arakawa S; Kamidono S; Hara I J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714 [TBL] [Abstract][Full Text] [Related]
4. Differential expressions of CD44 variants in tumors affecting the central nervous system. Resnick DK; Resnick NM; Welch WC; Cooper DL Mol Diagn; 1999 Sep; 4(3):219-32. PubMed ID: 10553022 [TBL] [Abstract][Full Text] [Related]
5. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Sridhar SC; Miranti CK Oncogene; 2006 Apr; 25(16):2367-78. PubMed ID: 16331263 [TBL] [Abstract][Full Text] [Related]
6. CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway. Liu YN; Tsai MF; Wu SG; Chang TH; Shih JY Life Sci; 2024 Jan; 336():122345. PubMed ID: 38092140 [TBL] [Abstract][Full Text] [Related]
7. Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression. Raso-Barnett L; Banky B; Barbai T; Becsagh P; Timar J; Raso E PLoS One; 2013; 8(1):e53883. PubMed ID: 23342032 [TBL] [Abstract][Full Text] [Related]
8. Effect of KAI1/CD82 on the beta1 integrin maturation in highly migratory carcinoma cells. Jee BK; Lee JY; Lim Y; Lee KH; Jo YH Biochem Biophys Res Commun; 2007 Aug; 359(3):703-8. PubMed ID: 17560548 [TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Manten-Horst E; Danen EH; Smit L; Snoek M; Le Poole IC; Van Muijen GN; Pals ST; Ruiter DJ Int J Cancer; 1995 Jun; 64(3):182-8. PubMed ID: 7542641 [TBL] [Abstract][Full Text] [Related]
10. Expression of CD44 and the pattern of CD44 alternative splicing in uveal melanoma. Danen EH; ten Berge PJ; van Muijen GN; Jager MJ; Ruiter DJ Melanoma Res; 1996 Feb; 6(1):31-5. PubMed ID: 8640067 [TBL] [Abstract][Full Text] [Related]
11. CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. Gasbarri A; Del Prete F; Girnita L; Martegani MP; Natali PG; Bartolazzi A Melanoma Res; 2003 Aug; 13(4):325-37. PubMed ID: 12883358 [TBL] [Abstract][Full Text] [Related]
12. KAI1/CD82, a tumor metastasis suppressor. Liu WM; Zhang XA Cancer Lett; 2006 Aug; 240(2):183-94. PubMed ID: 16260083 [TBL] [Abstract][Full Text] [Related]
13. KAI1/CD82 decreases Rac1 expression and cell proliferation through PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells. Choi UJ; Jee BK; Lim Y; Lee KH Cell Biochem Funct; 2009 Jan; 27(1):40-7. PubMed ID: 19107873 [TBL] [Abstract][Full Text] [Related]
14. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Bandyopadhyay S; Zhan R; Chaudhuri A; Watabe M; Pai SK; Hirota S; Hosobe S; Tsukada T; Miura K; Takano Y; Saito K; Pauza ME; Hayashi S; Wang Y; Mohinta S; Mashimo T; Iiizumi M; Furuta E; Watabe K Nat Med; 2006 Aug; 12(8):933-8. PubMed ID: 16862154 [TBL] [Abstract][Full Text] [Related]
15. The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activity. Zhou B; Liu L; Reddivari M; Zhang XA Cancer Res; 2004 Oct; 64(20):7455-63. PubMed ID: 15492270 [TBL] [Abstract][Full Text] [Related]
16. CD44 and the adhesion of neoplastic cells. Rudzki Z; Jothy S Mol Pathol; 1997 Apr; 50(2):57-71. PubMed ID: 9231152 [TBL] [Abstract][Full Text] [Related]
18. [Relationship between the levels of KAI1/CD82 and CD44 and the clinicopathological features of non-small cell lung cancer]. Chen QY; Lin XM; Zhou JY; An Z; Yang L; Jiang ZY Zhonghua Jie He He Hu Xi Za Zhi; 2004 Feb; 27(2):101-4. PubMed ID: 14990184 [TBL] [Abstract][Full Text] [Related]
19. KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line. Jee BK; Park KM; Surendran S; Lee WK; Han CW; Kim YS; Lim Y Biochem Biophys Res Commun; 2006 Apr; 342(2):655-61. PubMed ID: 16488391 [TBL] [Abstract][Full Text] [Related]
20. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Miranti CK Cell Signal; 2009 Feb; 21(2):196-211. PubMed ID: 18822372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]